- ISIN
- US6707031075
- CUSIP
- 670703107
- Delisting Date
- Jul 16, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 29, 2021
Highlights
- Market Cap
- $9.13B
- Enterprise Value
- $8.98B
- EPS (TTM)
- -$5.98
- EBITDA (TTM)
- -$362.61M
- Year Range
- $71.13 - $123.99
- Target Price
- $144.40
- ROA (TTM)
- -33.81%
- ROE (TTM)
- -38.32%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NUVL Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
Nuvalent, Inc. (NUVL) has returned 23.23% so far this year and 59.41% over the past 12 months.
Nuvalent, Inc.
- 1D
- 0.00%
- 1M
- 0.19%
- 6M
- 20.48%
- YTD
- 23.23%
- 1Y
- 59.41%
- 3Y*
- 42.16%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 47.35%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NUVL Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.29% | -0.91% | 0.49% | -2.12% | 10.08% | 11.88% | 0.37% | 23.23% | |||||
| 2025 | 9.62% | -12.62% | -5.41% | 8.22% | -2.79% | 2.27% | 2.69% | -2.26% | 12.93% | 14.85% | 10.10% | -8.01% | 28.50% |
| 2024 | 2.15% | 11.91% | -10.73% | -8.27% | -4.73% | 15.60% | 5.38% | 6.49% | 20.17% | -13.50% | 9.26% | -19.03% | 6.37% |
| 2023 | 1.58% | 0.13% | -13.87% | 35.65% | 18.96% | 0.17% | 18.21% | -8.59% | 0.88% | 13.31% | 25.49% | 12.57% | 147.11% |
| 2022 | -29.15% | 10.82% | -7.09% | -25.92% | -13.90% | 53.05% | 9.59% | 13.59% | 15.17% | 83.69% | -7.92% | -9.43% | 56.41% |
| 2021 | 0.83% | 99.62% | -38.10% | 8.34% | -12.69% | -10.74% | 5.19% |
Benchmark Metrics
Nuvalent, Inc. has an annualized alpha of 61.42%, beta of 1.43, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since July 29, 2021.
- This stock captured 277.91% of S&P 500 Index gains and 114.38% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 61.42%
- Beta
- 1.43
- R²
- 0.11
- Upside Capture
- 277.91%
- Downside Capture
- 114.38%
Return for Risk
Risk / Return Rank
NUVL ranks 77 for risk / return — above 77% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Nuvalent, Inc. (NUVL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NUVL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.63 | ||
| Sortino ratioReturn per unit of downside risk | -0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.25 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.16 | 2.00 | +0.15 |
| Martin ratioReturn relative to average drawdown | 5.76 | 8.49 | -2.73 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nuvalent, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nuvalent, Inc. was 80.70%, occurring on May 16, 2022. Recovery took 240 trading sessions.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-80.70%May 2022 | 8mo 10d | 11mo 20d | 1y 7moSep 2021 - May 2023 | Bear market2022 |
-47.12%Apr 2025 | 6mo 23d | 1y 2mo | 1y 8moSep 2024 - Jun 2026 | 2025 selloff2025 |
-29.48%Apr 2024 | 1mo 21d | 4mo 23d | 6mo 14dFeb 2024 - Sep 2024 | — |
-22.09%Oct 2023 | 14d | 1mo 8d | 1mo 22dOct 2023 - Nov 2023 | — |
-17.53%Aug 2023 | 16d | 1mo 18d | 2mo 4dAug 2023 - Oct 2023 | — |
Drawdown Indicators
| NUVL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -80.70% | -56.78% | -23.92% |
Max Drawdown (1Y)Largest decline over 1 year | -20.98% | -9.10% | -11.88% |
Max Drawdown (3Y)Largest decline over 3 years | -47.12% | -18.90% | -28.22% |
Max Drawdown (5Y)Largest decline over 5 years | -80.70% | -25.43% | -55.27% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.58% | +1.58% |
Average DrawdownAverage peak-to-trough decline | -24.67% | -10.70% | -13.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.84% | 2.14% | +5.70% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nuvalent, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nuvalent, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NUVL in comparison with other companies in the Biotechnology industry. Currently, NUVL has a P/B value of 8.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NUVL
Add Nuvalent, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NUVL